Jacobio Pharmaceuticals Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 207

Employees

  • Stock Symbol
  • 01167

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.51
  • (As of Friday Closing)

Jacobio Pharmaceuticals General Information

Description

Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Building 8
  • Number 105 Jinghai 3rd Road, BDA
  • Beijing, 101111
  • China
+86 010
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • Building 8
  • Number 105 Jinghai 3rd Road, BDA
  • Beijing, 101111
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Jacobio Pharmaceuticals Stock Performance

As of 20-Nov-2026, Jacobio Pharmaceuticals’s stock price is $0.51. Its current market cap is $401M with 782M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.51 $0.53 $0.50 - $1.19 $401M 782M 1.78M $0.10

Jacobio Pharmaceuticals Financials Summary

As of 30-Jun-2026, Jacobio Pharmaceuticals has a trailing 12-month revenue of $106M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 344,269 513,357 10,399 215,387
Revenue 105,573 7,443 21,700 8,978
EBITDA 73,402 (19,738) (22,537) (52,693)
Net Income 73,404 (20,300) (21,700) (50,760)
Total Assets 274,249 186,420 186,185 206,032
Total Debt 23,521 23,606 20,832 29,613
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Jacobio Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Jacobio Pharmaceuticals‘s full profile, request access.

Request a free trial

Jacobio Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and d
Pharmaceuticals
Beijing, China
207 As of 2026

Lexington, MA
 

Sugar Land, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Jacobio Pharmaceuticals Competitors (43)

One of Jacobio Pharmaceuticals’s 43 competitors is Dicerna Pharmaceuticals, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Tvardi Therapeutics Formerly VC-backed Sugar Land, TX
Immutep Corporation Sydney, Australia
Amunix Pharmaceuticals Formerly PE-Backed South San Francisco, CA
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
You’re viewing 5 of 43 competitors. Get the full list »

Jacobio Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Jacobio Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Jacobio Pharmaceuticals‘s full profile, request access.

Request a free trial

Jacobio Pharmaceuticals Investments (1)

Jacobio Pharmaceuticals’s most recent deal was a Later Stage VC with HebeCell for . The deal was made on 31-Aug-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
HebeCell 31-Aug-2021 Later Stage VC Other Healthcare Technology Systems
To view Jacobio Pharmaceuticals’s complete investments history, request access »

Jacobio Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

28.21 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Jacobio Pharmaceuticals’s complete esg history, request access »

Jacobio Pharmaceuticals FAQs

  • When was Jacobio Pharmaceuticals founded?

    Jacobio Pharmaceuticals was founded in 2015.

  • Where is Jacobio Pharmaceuticals headquartered?

    Jacobio Pharmaceuticals is headquartered in Beijing, China.

  • What is the size of Jacobio Pharmaceuticals?

    Jacobio Pharmaceuticals has 207 total employees.

  • What industry is Jacobio Pharmaceuticals in?

    Jacobio Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Jacobio Pharmaceuticals a private or public company?

    Jacobio Pharmaceuticals is a Public company.

  • What is Jacobio Pharmaceuticals’s stock symbol?

    The ticker symbol for Jacobio Pharmaceuticals is 01167.

  • What is the current stock price of Jacobio Pharmaceuticals?

    As of 20-Nov-2026 the stock price of Jacobio Pharmaceuticals is $0.51.

  • What is the current market cap of Jacobio Pharmaceuticals?

    The current market capitalization of Jacobio Pharmaceuticals is $401M.

  • What is Jacobio Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Jacobio Pharmaceuticals is $106M.

  • Who are Jacobio Pharmaceuticals’s competitors?

    Dicerna Pharmaceuticals, Tvardi Therapeutics, Immutep, Amunix Pharmaceuticals, and Alnylam Pharmaceuticals are some of the 43 competitors of Jacobio Pharmaceuticals.

  • What is Jacobio Pharmaceuticals’s annual earnings per share (EPS)?

    Jacobio Pharmaceuticals’s EPS for 12 months was $0.10.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process